rofecoxib has been researched along with Stroke in 36 studies
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 9.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "The association between rofecoxib use and ischemic stroke has not been shown in clinical trials." | 7.74 | Long-term risk of ischemic stroke associated with rofecoxib. ( Afilalo, J; Coussa-Charley, MJ; Eisenberg, MJ, 2007) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 5.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "Overall, the use of NSAIDs is not associated with an increased risk of hemorrhagic stroke, although this risk was modestly significantly elevated in diclofenac and meloxicam users." | 4.93 | Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. ( Matteson, EL; Thongprayoon, C; Ungprasert, P, 2016) |
| "It can be postulated that in addition to the risk of heart attack and stroke, rofecoxib users were at increased risk of hemorrhage, in addition to other thrombotic and embolic adverse events, which was exacerbated in those taking blood thinners or NSAIDs." | 3.75 | Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002. ( Barry, WT; Bottone, FG, 2009) |
| " Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0." | 3.75 | Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009) |
| " Ischemic stroke was predicted by hypertension, myocardial infarction, low-dose aspirin, comorbidity score, Health Assessment Questionnaire score, and presence of total joint replacement, but not by diabetes, smoking, exercise, or body mass index." | 3.74 | Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. ( Hallenbeck, JM; Michaud, K; Nadareishvili, Z; Wolfe, F, 2008) |
| "The association between rofecoxib use and ischemic stroke has not been shown in clinical trials." | 3.74 | Long-term risk of ischemic stroke associated with rofecoxib. ( Afilalo, J; Coussa-Charley, MJ; Eisenberg, MJ, 2007) |
| "Using national data (2001-2003), this study explored the risk of acute myocardial infarction (AMI), angina, stroke and transient ischaemic attack (TIA) in long-term users of rofecoxib and celecoxib in Taiwan and compared this data with that for those using meloxicam." | 3.73 | Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. ( Hsiao, FY; Huang, WF; Shih, YT; Tsai, YW; Wen, YW, 2006) |
| "Rofecoxib use was associated with acute cerebrovascular events (Empirical Bayes Geometric Mean ratio 1." | 1.35 | Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. ( Cheng, H; Curtis, JR; Delzell, E; Dumouchel, W; Fram, D; Kilgore, M; Saag, K; Yun, H, 2008) |
| "Celecoxib and naproxen were not associated with increased risks." | 1.35 | Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. ( Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J, 2008) |
| "Among 7." | 1.33 | Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? ( Coupal, L; Grover, SA; Zowall, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 31 (86.11) | 29.6817 |
| 2010's | 3 (8.33) | 24.3611 |
| 2020's | 2 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Moore, N | 1 |
| Jordan, F | 1 |
| Quinn, TJ | 1 |
| McGuinness, B | 1 |
| Passmore, P | 1 |
| Kelly, JP | 1 |
| Tudur Smith, C | 1 |
| Murphy, K | 1 |
| Devane, D | 1 |
| Zhang, Y | 1 |
| Hoda, MN | 1 |
| Zheng, X | 1 |
| Li, W | 1 |
| Luo, P | 1 |
| Maddipati, KR | 1 |
| Seki, T | 1 |
| Ergul, A | 1 |
| Wang, MH | 1 |
| Ungprasert, P | 1 |
| Matteson, EL | 1 |
| Thongprayoon, C | 1 |
| Nadareishvili, Z | 1 |
| Michaud, K | 1 |
| Hallenbeck, JM | 1 |
| Wolfe, F | 1 |
| Curtis, JR | 1 |
| Cheng, H | 1 |
| Delzell, E | 1 |
| Fram, D | 1 |
| Kilgore, M | 1 |
| Saag, K | 1 |
| Yun, H | 1 |
| Dumouchel, W | 1 |
| Bottone, FG | 1 |
| Barry, WT | 1 |
| Ray, WA | 1 |
| Varas-Lorenzo, C | 1 |
| Chung, CP | 1 |
| Castellsague, J | 1 |
| Murray, KT | 1 |
| Stein, CM | 1 |
| Daugherty, JR | 1 |
| Arbogast, PG | 1 |
| García-Rodríguez, LA | 1 |
| Bäck, M | 1 |
| Yin, L | 1 |
| Ingelsson, E | 1 |
| Topol, EJ | 2 |
| Couzin, J | 2 |
| Lenzer, J | 2 |
| Sibbald, B | 1 |
| Pemberton, MN | 1 |
| Grover, SA | 1 |
| Coupal, L | 1 |
| Zowall, H | 1 |
| Giaquinta, D | 1 |
| Dyer, C | 1 |
| Fendrick, AM | 1 |
| Idänpään-Heikkilä, JE | 1 |
| Klaukka, T | 1 |
| Karha, J | 1 |
| Weinberg, JM | 1 |
| Wadman, M | 1 |
| Huang, WF | 1 |
| Hsiao, FY | 1 |
| Tsai, YW | 1 |
| Wen, YW | 1 |
| Shih, YT | 1 |
| Avorn, J | 1 |
| Roth-Cline, MD | 1 |
| Nelson, NJ | 1 |
| Höer, A | 1 |
| Häussler, B | 1 |
| Chou, R | 1 |
| Fu, R | 1 |
| Carson, S | 1 |
| Saha, S | 1 |
| Helfand, M | 1 |
| Afilalo, J | 1 |
| Coussa-Charley, MJ | 1 |
| Eisenberg, MJ | 1 |
| Andersohn, F | 1 |
| Cunnington, M | 1 |
| Webb, D | 1 |
| Qizilbash, N | 1 |
| Blum, D | 1 |
| Mander, A | 1 |
| Funk, MJ | 1 |
| Weil, J | 1 |
| Josefson, D | 1 |
| Schnitzer, TJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645] | Phase 2 | 60 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for rofecoxib and Stroke
| Article | Year |
|---|---|
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiotoxicity; Cardiovascular Diseases; Cyclooxygenase 2 I | 2020 |
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Age | 2020 |
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cerebral Hemorrhage; Diclofenac; Humans; Ibuprof | 2016 |
Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions.
Topics: Biomedical Research; Cyclooxygenase 2 Inhibitors; Endarterectomy, Carotid; Humans; Lactones; Researc | 2007 |
32 other studies available for rofecoxib and Stroke
| Article | Year |
|---|---|
Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Ischemia; Cell Line, Tumor; Cell Prol | 2014 |
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An | 2008 |
Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; | 2008 |
Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Interactions; Dr | 2009 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C | 2009 |
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic | 2012 |
Failing the public health--rofecoxib, Merck, and the FDA.
Topics: Adverse Drug Reaction Reporting Systems; Advertising; Arthritis, Rheumatoid; Clinical Trials as Topi | 2004 |
Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
Topics: Blood Pressure; Clinical Trials as Topic; Colonic Polyps; Cyclooxygenase Inhibitors; Drug and Narcot | 2004 |
US government agency to investigate FDA over rofecoxib.
Topics: Drug Approval; Humans; Interprofessional Relations; Lactones; Myocardial Infarction; Stroke; Sulfone | 2004 |
Rofecoxib (Vioxx) voluntarily withdrawn from market.
Topics: Drug and Narcotic Control; Drug Industry; Humans; Lactones; Myocardial Infarction; Randomized Contro | 2004 |
Rofecoxib and dental prescribing.
Topics: Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Pharmacopoeias as Topic; Stroke; | 2004 |
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; C | 2005 |
Lessons learned after the withdrawal of rofecoxib.
Topics: Clinical Trials as Topic; Cyclooxygenase Inhibitors; Decision Making, Organizational; Humans; Lacton | 2004 |
UK patients seek compensation after taking rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Compensation and Redress; Humans; La | 2004 |
Vioxx removed from market.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Lactones; Myocardial Infarction; Stroke; Sulfones | 2004 |
COX-2 inhibitor use after Vioxx: careful balance or end of the rope?
Topics: Contraindications; Cyclooxygenase Inhibitors; Drug Industry; Humans; Lactones; Myocardial Infarction | 2004 |
[Rofecoxib (Vioxx) has been withdrawn, what next?].
Topics: Dose-Response Relationship, Drug; Drug and Narcotic Control; Finland; Forecasting; Humans; Lactones; | 2004 |
The sad story of Vioxx, and what we should learn from it.
Topics: Arthritis, Rheumatoid; Drug Approval; Drug Industry; Humans; Lactones; Myocardial Infarction; Produc | 2004 |
FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke.
Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Lactones; Membrane | 2005 |
Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cy | 2005 |
The lessons of Vioxx.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2005 |
Drug safety special: the safety catch.
Topics: Adverse Drug Reaction Reporting Systems; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; He | 2005 |
Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Celecoxib; | 2006 |
Evaluating drug effects in the post-Vioxx world: there must be a better way.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug | 2006 |
Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug | 2006 |
Celecoxib shown effective in preventing colon polyps.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib | 2006 |
[Overestimated].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Controlled Clinical Trials as Topi | 2006 |
Long-term risk of ischemic stroke associated with rofecoxib.
Topics: Adenomatous Polyps; Brain Ischemia; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Female; Follo | 2007 |
Cerebrovascular events after discontinuation of rofecoxib treatment.
Topics: Brain Ischemia; Cyclooxygenase 2 Inhibitors; Humans; Incidence; Lactones; Risk; Stroke; Sulfones | 2007 |
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coh | 2008 |
FDA warns Merck over its promotion of rofecoxib.
Topics: Anticoagulants; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Drug Interactio | 2001 |
Is concern about cardiovascular events with the new coxib class of drugs justified?
Topics: Celecoxib; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Drug Evaluation; Humans; Lac | 2001 |